Wareham tenant appreciation days. |
|
We were absolutely delighted with the great turnout at the tenant appreciation days at both our EmeryStation Research Campus and Aquatic Park Research Campus. Fabulous company, delicious food and great music. We'll do this more often! |
|
Congratulations to Rachel Haurwitz. |
|
Our heartfelt congratulations to Rachel Haurwitz, Ph. D, President and CEO of Caribou Biosciences, who was just recognized as one of the Most Admired CEOs by the San Francisco Business Times.
Caribou first became our tenant at our QB3 East Bay Innovation Center shortly after Rachel became CEO at age 26. Our Wareham team has watched with great respect as she has steered her team to growing their foothold at our research campuses in both Berkeley and Emeryville, while successfully taking Caribou public. See exciting Caribou news below.
|
|
Join us for Biocom event at our EmeryStation Research Campus. |
|
December 8, 4:00-6:00 pm
EmeryStation Wintergarden
5858 Horton Street, Emeryville
|
|
Wareham is hosting the annual Biocom California Bay Area Facilities Reception at our EmeryStation Research Campus.
Geared toward facility managers and service providers but is open to all. This is a casual event to mingle with other facility managers and enjoy interaction with other colleagues.
Admission is complimentary for Biocom California, IFMA, and ISPE members. Others may attend for an admission fee of $35. Register now as rates will increase onsite.
|
|
November FDA actions and other recent tenant news to celebrate. |
|
Great news from these tenants on FDA clearances and other achievements. Congratulations to all!
-
Caribou Biosciences just announced that the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track Designations to CB-010, an Allogeneic Anti-CD19 CAR-T Cell Therapy. This announcement came on the heels of Caribou's announcement of FDA Clearance of IND Application for CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma.
-
Upside Foods cleared an important FDA hurdle on its path to commercialization of cell-cultivated meat when it received a letter of no questions from the FDA .
-
Kyverna Therapeutics announced FDA Clearance of IND for KYV-101, a Novel Fully Human CD19 CAR T-Cell Therapy to Treat Lupus Nephritis.
-
4D Molecular Therapeutics announced Interim Clinical Data from On-going Phase 1/2 Clinical Trial of Intravitreal 4D-150 for Wet Age-Related Macular Degeneration (wet AMD).
-
Nutcracker Therapeutics reported strong anti-tumor responses of lead mRNA immunotherapy in preclinical data at SITC Annual Meeting 2022.
-
Amyris, Inc., accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform, announced record consumer sales performance during this year's Black Friday sales week from November 18-26.
-
Catalent announced that it had entered into a New License Agreement for three Antibody-Drug Conjugate Programs with the Potential to Accelerate Exelixis’ Biologics Pipeline.
-
Pivot Bio announced that it joins the Agriculture Innovation Mission for Climate as an Innovation Sprint Partner, committing at least $291 million in product development funding over four years to accelerate the adoption of climate-resilient microbial nitrogen fertilizers.
-
Ligand Pharmaceuticals announced the company has completed the expected tax-free spin-off of its OmniAb antibody discovery business which has become OmniAb, Inc., an independent publicly traded company. OmniAb began on NASDAQ under the stock ticker symbol “OABI.” Ligand continues to trade under the stock ticker symbol “LGND.”
-
The Joint BioEnergy Institute announced that inventor Deepika Awasthi, a project scientist in the Microbial & Enzyme Discovery group in JBEI’s Deconstruction Division, won the 2022 Berkeley Lab Pitch Competition held on October 27. The competition, funded by the Department of Energy (DOE) and co-hosted by the Berkeley Lab Intellectual Property Office and the UC Berkeley Haas School of Business, was designed to provide scientist-entrepreneurs at the Lab with experience in pitching to key stakeholders such as potential investors and partners.
-
Gritstone Bio announced Updated Overall Survival Results from GRANITE Phase 1/2 Study and Poster at SITC 2022.
-
Sangamo Therapeutics announced that Phase 3 trial of investigational gene therapty for hemophilia A has resumed dosing.. All trial sites are anticipated to be active by the end of 2022 and a pivotal readout is expected in the first half of 2024.
-
Ginkgo Bioworks, which is building the leading platform for cell programing and biosecurity, announced the sale of shares of its Class A common stock for gross proceeds of approximately $100 million. Ginkgo also recently announced that it completed its acquisition of Zymergen; began a collaboration with Bolt Threads which builds on the existing relationship between the partners following existing b-silk™ protein optimization project.
-
Berkeley Lights, Inc. announced the launch of the Opto® Memory B Discovery Rabbit workflow, expanding the diversity of antibodies customers can discover on the Beacon® platform.
-
Eureka Therapeutics announced 1) a license with the National Cancer Institute to Advance GPC2 ARTEMIS® T Cell Therapy for Neuroblastoma and 2) that it received Orphan Drug Designations for Treatment of Hepatoblastoma with ET140203 ARTEMIS® T cells.
-
Perfect Day announced earlier this fall that it has deepened its investment in enterprise biology business with a new brand identity, nth Bio, and also announced a partnership with Onego Bio.
|
|
Restaurants serving our campuses and cities. |
|
Please continue to support these popular and loved restaurants serving our campuses and cities.
Check out their websites, call, or order from your favorite restaurant app. Many of them cater your lunches and meetings as well.
|
|
Remember to take advantage of these other campus amenities. |
|
Conference rooms to reserve, fitness centers, bike parking and bike repair stations, pockets parks, art, and gardens may be found throughout our campuses. The new EmeryStation conference center opens soon! |
|
And did we mention that we love bikes! |
|
What Else You Need to Know |
|
- A new sculpture will be installed at our Aquatic Park Research Campus in early December!
- Our December newsletter will highlight the STEAM nonprofits serving our schools, cities and neighborhoods with opportunities for mentoring and giving.
|
|
1120 Nye Street, Suite 400, San Rafael, CA 94901
415.457.4964
|
|
|
Distinguished buildings for noble and Nobel scientists. Emeryville | Berkeley | Richmond | Palo Alto | Marin
|
|
|
|
|
|
|
